Browse by author
Lookup NU author(s): Dr Bridget Griffiths
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
The assessment of disease activity in systemic lupus erythematosus (SLE) is a task faced by clinicians in every day care, but it is also required for clinical research and in randomised controlled trials. It is crucial to distinguish disease activity from infection, chronic damage and co-morbid disease. Over the past 20 years, many indices have been developed to objectively measure lupus disease activity and several of these have been validated. The most widely used indices are the British Isles Lupus Assessment Group (BILAG) index, the European Consensus Lupus Activity Measurement (ECLAM), the Systemic Lupus Activity Measure (SLAM), the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and the Lupus Activity Index (LAI). All these indices have been validated and have excellent reliability, validity and responsiveness to change. In addition to the assessment of disease activity, the evaluation of damage using the validated SLICC/ACR damage index and health-related quality of life is advised for clinical research.
Author(s): Griffiths B, Mosca M, Gordon C
Publication type: Article
Publication status: Published
Journal: Best Practice & Research: Clinical Rheumatology
Year: 2005
Volume: 19
Issue: 5
Pages: 685-708
ISSN (print): 1532-1770
ISSN (electronic):
Publisher: Bailliere Tindall
URL: http://dx.doi.org/10.1016/j.berh.2005.03.010
DOI: 10.1016/j.berh.2005.03.010
Altmetrics provided by Altmetric
